News

PhIP-Seq analysis in the Boston Birth Cohort found distinct early-childhood IgG patterns in food allergy, but investigators caution against diagnostic use of IgG testing.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Lilly’s groundbreaking new Zepbound administration option.

FDA approves dupilumab for allergic fungal rhinosinusitis, supported by phase 3 LIBERTY-AFRS-AIMS data showing reduced symptoms and corticosteroid or surgery use.

HCPLive speaks with Mark Lebwohl, MD, about recent data on those with psoriasis and obesity or overweight treated with ixekizumab (Taltz) and tirzepatide (Zepbound).

The list price of all 3 semaglutide drugs will be lowered to $675, marking a reduction of roughly 50% and 35% for Wegovy and Ozempic, respectively.

In a phase 2 trial in Chinese people with overweight or obesity, UBT251 led to mean weight loss of up to 19.7% (-17.5 kg) after 24 weeks.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the Portal Pump's recent Breakthrough Designation from the FDA.

KONFIDENT investigator Cancian discusses oral sebetralstat’s role in the updated HAE treatment guidelines.

An audio recap of the top 5 stories in healthcare news from the week of 02/15-02/21.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent release of the Eversense 365 by Sequel Medtech and Senseonics, paired with the Twiist insulin pump.

Seralutinib did improve 6-minute walk times and biomarkers, especially in patients with higher-risk disease.

Luspatercept met primary endpoints in transfusion-dependent and non–transfusion-dependent alpha-thalassemia.

This approval of the Allurion Gastric Balloon System, incorporating the Allurion Smart Capsule, is indicated for weight loss management for those with obesity.

The phase 3 REDEFINE 4 trial saw CagriSema achieve 23% weight loss, but fail to demonstrate noninferiority to tirzepatide in patients with overweight or obesity.

The FDA has granted both designations to TSRA-196, an in vivo gene editing program from Tessera Therapeutics, for the treatment of PiZZ alpha-1 antitrypsin deficiency.

FDA clears iloperidone metabolite, milsaperidone, for acute bipolar I disorder and schizophrenia, expanding treatment options.

Cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the recent release of Eli Lilly's Zepbound as an injectable with the KwikPen.

The CUPID-C randomized clinical trial confirmed CUPID-A results, with dupilumab significantly reducing urticaria in anti-IgE–naive individuals with CSU.

Levine discusses 24-hour adverse event resolution, retreatment questions, and scalability of supervised psilocybin therapy for treatment-resistant depression.

This interview segment highlights additional points on bimekizumab and psoriasis related to patient-reported outcomes (PROs) in the 3 year BE RADIANT study.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the Portal implanted insulin pump, which has received Breakthrough Device designation from the FDA.

The new joint guidelines include a clinical classification system, major contributing factors, and recommendations for treatment and follow-up.

In this segment of his interview, Vender highlighted his own views on the significance of BE RADIANT trial findings on bimekizumab for psoriasis.

Levine breaks down Compass Pathways’ phase 3 data on COMP360, highlighting next-day onset and sustained symptom improvement through 26 weeks.

SEQUENCE trial data highlight sustained 3-year clinical and endoscopic remission with risankizumab in anti-TNF–exposed Crohn’s patients.

1 year into real-world use, 4 clinicians discuss how semaglutide is transforming the endocrinology, nephrology, and cardiology landscape.